The treatment landscape for patients with prostate cancer, especially individuals with advanced disease, has dramatically ...

During Movember, Michaela Hagenhofer, general manager, commercial operations at Johnson & Johnson Innovative Medicine, ...

While prostate cancer affects about 1 in 8 men, when it's caught early, there's a 99% survival rate, according to Cancer.org.

Intravenous; mCRPC: Metastatic castration-resistant prostate ... Androgen deprivation is the mainstay of therapy of advanced prostate cancer treatment, but the cure rate is low and patients ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, ...

Prostate cancer is the most common cancer in men, with an estimated one in eight Canadian men expected to be diagnosed in ...

ANDROGEN deprivation therapy (ADT) has been the cornerstone of treatment for advanced castration-sensitive prostate cancer ...

A recent study led by Cedars-Sinai researchers reveals that a growing number of older men in the U.S. with intermediate or ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...

According to the 2019 National Cancer Registry the lifetime risk for prostate cancer in South Africa is 1 in every 15 man.

When prostate cancer cells burst as a result of menadione treatment, there is no risk of metastasis. This event represents a ...